

The Misdiagnosis of Beta-Thalassemia Heterozygosity Led by Hyperthyroidism

Likhasit Sanglutong¹, Somchai Insiripong², Wattana Insiripong³

¹ Department of Medicine, Bangkok Hospital Muangraj, Ratchaburi, Thailand

² Department of Medicine, Saint Mary's Hospital, Nakhon Ratchasima, Thailand

³ Department of General Practice, Nopparat Rajathanee Hospital, Bangkok, Thailand

When patients have mild microcytic hypochromic anemia with slightly increased hemoglobin (Hb) A₂ fraction, the most likely diagnosis is beta-thalassemia heterozygosity. But herein we found a patient who had all these hematological parameters but did not have beta-thalassemia heterozygosity. He was a 14-year-old Thai who presented with fatigue and heat intolerance for 2 weeks. His physical examination revealed mild diffuse enlargement of thyroid gland. Blood tests showed Hb 120 g/L, mean corpuscular volume (MCV) 72.1 fL, mean corpuscular hemoglobin (MCH) 23.3 pg/cell, free triiodothyronine (FT₃) > 20 pg/mL, free thyroxine (FT₄) > 5.0 ng/dL, thyrotropin < 2.5 mIU/L, serum ferritin 51.3 µg/L, Hb A₂ 3.8%. Besides primary hyperthyroidism, he was diagnosed with beta-thalassemia heterozygosity. After being treated with antithyroid drug for 6 months, his blood tests showed subclinical hyperthyroidism, Hb 146 g/L, MCV 83.3 fL, MCH 26.3 pg/cell, Hb A₂ 3.0%. Not only the thyroid hormones levels but also the Hb concentration, MCV, and the Hb A₂ percentage became normal. Due to this inconsistency, the DNA analysis for beta-thalassemia genes was performed and found negative for numerous common and rare beta-thalassemia genes meanwhile beta-globin gene sequencing appeared normal. It should be concluded that hyperthyroidism could induce slightly elevated Hb A₂ percentage and mild hypochromic microcytic anemia in a normal individual, leading to the misdiagnosis of beta-thalassemia heterozygosity. In other words, Hb analysis should not be performed during hyperthyroidism and it should be delayed till achievement of the euthyroid stage.

Keywords: Hyperthyroidism, Fake Beta, Thalassemia, Heterozygosity

Rama Med J: doi:10.33165/rmj.2022.45.3.256975

Received: March 27, 2022 **Revised:** September 1, 2022 **Accepted:** September 16, 2022

Corresponding Author:

Likhasit Sanglutong

Department of Medicine,
Bangkok Hospital Muangraj,
59/3 Phetchkasem Road,
Na Muang, Muang Ratchaburi,
Ratchaburi 70000, Thailand.

Telephone: +668 4911 5775

E-mail: lickhasit1986@gmail.com





Introduction

Thalassemia is a group of hereditary disease due to genetic transmission of defect of globin chain synthesis. It is mainly classified into alpha and beta-thalassemia depending on the globin chain involved. Most of them are characterized by microcytic hypochromic anemia of that the degree can vary from asymptomatic to transfusion-dependent or still birth. For individuals with beta-thalassemia heterozygosity or traits, they usually have mild microcytic hypochromic anemia, hemoglobin (Hb) concentration ranging from 106 ± 19 to 133 ± 17 g/L,¹ mean corpuscular volume (MCV) 63.8 ± 4.2 fL for beta(0), 67.0 ± 5.5 fL for beta(+), and mean corpuscular hemoglobin (MCH) 20.1 ± 1.4 pg/cell for beta(0), 21.2 ± 1.9 pg/cell for beta(+) thalassemia traits.² Hb analysis mostly shows only mildly increased hemoglobin A₂ (alpha₂ delta₂) percentage, 3.5 - 5.7 %, mean 4.9 ± 0.4 %.³ Although all these characteristics are genetically transmitted, they can be minimally modified by some acquired factors, for instance, in beta-thalassemia heterozygosity complicated by iron deficiency anemia: Hb concentration decreases from 108 ± 11 to 98 ± 11 g/L, MCV from 67.9 ± 4.8 to 64.0 ± 6.4 fL, MCH from 21.5 ± 3.0 to 20.0 ± 3.0 pg/cell, and Hb A₂ from 5.8 ± 0.9 % to 5.4 ± 0.9 %.⁴

On the contrary, we found a patient who had all these hematological parameters during hyperthyroidism that firstly led to misdiagnosis of beta-thalassemia heterozygosity but later they all became normal after hyperthyroidism was well controlled with medication.

Case Report

A 14-year-old Thai man was definitely diagnosed with primary hyperthyroidism based on the history of 2-week fatigue, heat intolerance without weight loss and diffusely mild enlargement of thyroid gland, no exophthalmos, heart rate 100 beats/min regularly on the physical examination whereas his first thyroid function test showed free triiodothyronine (FT₃) > 20.0 pg/mL (normal 1.71 - 3.71), free thyroxine (FT₄) > 5.0 ng/dL (normal

0.7 - 1.48), thyrotropin < 2.5 mIU/L (normal 0.4 - 4.0), antithyroxineperoxidase antibody 6.4 IU/mL (normal < 9), and antithyroglobulin antibody < 0.9 IU/mL (normal < 4).

Blood tests before starting antithyroid drug showed Hb 120 g/L, hematocrit (Hct) 37.2%, white blood cell (WBC) 8.5×10^9 /L, platelet 341×10^9 /L, neutrophil 56.6%, lymphocyte 31.5%, MCV 72.1 fL, MCH 23.3 pg/cell, mean corpuscular hemoglobin concentration (MCHC) 32.3 g/dL, red blood cell distribution width (RDW) 13.4%, and serum ferritin 51.3 µg/L. Hb analysis using the capillary zone electrophoresis method revealed A₂A, Hb A₂ 3.8%, Hb A 96.2%. The interpretation was beta-thalassemia heterozygosity with or without alpha thalassemia trait. The polymerase chain reaction (PCR) for alpha thalassemia was performed and showed negative for alpha thalassemia-1 genes (Southeast Asian and Thai deletions), negative for Southeast Asian Ovalocyte (SAO) gene, negative for alpha-globin gene triplication and negative for alpha thalassemia-2 (3.7 kb and 4.2 kb deletions, Hb Constant Spring and Hb Pakse genes). Hence, the hematological diagnosis of beta-thalassemia heterozygosity was definitely concluded. And genetic counseling was offered to him.

He was treated with methimazole 30 mg, propranolol 20 mg as well as 2 iron tablets a day. He could tolerate drug well, no neutropenia in the first month: Hb 138 g/L, Hct 42.3%, WBC 7.4×10^9 /L, platelet 438×10^9 /L, MCV 75.9 fL, MCH 24.7 pg/cell, MCHC 32.5 g/dL, RDW 13.4%, so antithyroid drug and iron tablets were regularly continued until he achieved euthyroidism in 3 months and antithyroid drug was gradually tapered.

After completion of 6 months of treatment, his blood tests showed FT₃ 4.87 pg/mL, FT₄ 1.78 ng/dL, thyrotropin 0.143 mIU/L, Hb 146 g/L, Hct 45.8%, WBC 7.5×10^9 /L, platelet 336×10^9 /L, MCV 83.3 fL, MCH 26.3 pg/cell, MCHC 31.9 g/dL, RDW 12.9%, serum ferritin 193 µg/L. Whereas his hyperthyroidism had turned from full blown to subclinical, the mild anemia and microcytosis became normal, therefore Hb analysis using the old method was repeated A₂A, Hb A₂ 3.0%, Hb F 0.3%.

Many hematological parameters that used to lead to the interpretation as beta-thalassemia heterozygosity during



hyperthyroidism became normal during euthyroidism. So, DNA analysis for beta-thalassemia was performed and found negative for all 10 common beta(0) and negative for 7 rare beta(+), and negative for 14 rare beta(0) thalassemia genes. And it was further confirmed with the whole beta-globin gene sequencing which was apparently normal. It was concluded that hyperthyroidism could temporarily induce many hematological parameters of a normal person to be closely similar to those of beta-thalassemia heterozygosity and all turned to normal after euthyroidism was achieved.

Discussion

When definite diagnosis of primary hyperthyroidism had been concluded,⁵ our case was misdiagnosed as beta-thalassemia heterozygosity because he had mild anemia, Hb 120 g/L, with mild microcytosis (MCV 72.1 fL), mild hypochromia (MCH 23.3 pg/cell), and mildly increased Hb A₂ percentage, 3.8%, that were perfectly consistent with parameters belonging to beta-thalassemia heterozygosity, MCV 67.0 ± 5.5 fL, MCH 21.2 ± 1.9 pg/cell, Hb A₂ 3.5 - 5.7 %, Hb concentration range from 106 ± 19 to 133 ± 17 g/L. His serum ferritin was normal (51.3 μ g/L), more than 30 μ g/L, hence iron deficiency anemia, another one of two common causes of microcytic anemia could be excluded.⁶

Basically, thyroid hormones can enhance erythropoiesis and delta globin chain synthesis.⁷ Jaafer et al⁸ showed the significant increase of Hb A₂ percentage in hyperthyroidism as compared with normal control, 2.77 ± 0.01 % vs 2.3 ± 0.01 %. But it did not reach 3.5%, the initial cut point for distinguishing beta-thalassemia heterozygosity from the control. In contrast, Hb A₂ in our case was 3.8% while the serum ferritin was adequate (51.3 μ g/L) during hyperthyroidism. One of common causes of the decrease of percentage of Hb A₂ in beta-thalassemia heterozygosity is iron deficiency⁴ anemia but it was not shown in Jaafer's study.

Characteristics of beta-thalassemia heterozygosity, Hct 35%, MCV 72 fL, MCH 27 pg/cell, MCHC 34 g/dL,

Hb A₂ 4.5% in Graves' disease used to be recognized in a Mediterranean man since 1994. After euthyroidism achievement, many parameters became normal, Hct 45% and Hb A₂ 2.8%⁹ although the MCV and MCH were not mentioned. Moreover, the DNA analysis for beta-thalassemia was not demonstrated, either. In contrast, both MCV and MCH turned normal in euthyroidism in our case.

Besides hyperthyroidism, some authorities demonstrated the slightly higher percentage of Hb A₂ alone should not be generally the only one tool for making the diagnosis of beta-thalassemia heterozygosity because among 38 cases with beta-thalassemia traits which were proved with DNA sequencing; 7 cases had Hb A₂ < 3%, 3 cases had Hb A₂ 3.1 - 3.9 %, the remainder (28 cases) had Hb A₂ > 4%. On the contrary, among 189 normal cases, 179 cases had Hb A₂ < 3%, 8 cases had Hb A₂ 3.1 - 3.9 %, and 2 cases had Hb A₂ level above 4%.¹⁰

Hb concentration, MCV, and MCHC were found significantly low in only 38%, 8%, and 4% of hyperthyroidism, respectively, as compared with normal control.¹¹ Severity of the decrease of any parameter was not enough to suspect beta-thalassemia heterozygosity: Hb 124 ± 13 to 125 ± 14 g/L, MCV 81.3 ± 8.6 to 81.7 ± 8.3 fL, and MCH 26.9 ± 2.7 to 27.0 ± 3.6 pg/cell, as compared with 136 ± 12 g/L, 85.0 fL, 29.3 ± 2.9 pg/cell, respectively.^{12,13} In addition, because iron deficiency anemia can be found in 0.9% or more of Graves' disease patients,^{14,15} and it can contribute all these low parameters, so it should be concurrently explored in any microcytic anemic patient also.

Thyroid hormones could directly enhance erythropoiesis via the Krüppel-like factor 9 (KLF9) acting at thyroid hormone receptor-alpha that is essential for regulating erythropoiesis¹⁶ or via increased erythropoietin through augmented accumulation of hypoxia-inducible factor-1.¹⁷ Moreover, without iron deficiency, hyperthyroidism could induce microcytosis which would become normocytosis after euthyroidism achievement and the microcytosis could reappear again when the hyperthyroidism recurred,¹⁸ the difference of MCV between hyperthyroidism and euthyroidism stages was 6 ± 3.5 fL.¹⁹ The underlying mechanism of microcytosis in hyperthyroidism has not



been well understood but may be due to an ineffective erythropoiesis²⁰ or thyroid hormone itself because it was found in cats that the higher serum total thyroxine, the higher percentage of microcytosis was and there was no correlation between the time elapse from the first diagnosis of hyperthyroidism and the MCV.²¹⁻²²

Conclusions

Hyperthyroidism seemed to lead the misdiagnosis of beta-thalassemia heterozygosity in a normal person. Hence, Hb analysis should not be performed during hyperthyroidism.

References

1. Zhang J, He J, Mao X, et al. Haematological and electrophoretic characterisation of β -thalassaemia in Yunnan province of Southwestern China. *BMJ Open*. 2017;7(1):e013367. doi:10.1136/bmjopen-2016-013367
2. Gu H, Wang YX, Du MX, Xu SS, Zhou BY, Li MZ. Effectiveness of using mean corpuscular volume and mean corpuscular hemoglobin for beta-thalassemia carrier screening in the Guangdong population of China. *Biomed Environ Sci*. 2021;34(8):667-671. doi:10.3967/bes2021.094
3. Ou Z, Li Q, Liu W, Sun X. Elevated hemoglobin A2 as a marker for β -thalassemia trait in pregnant women. *Tohoku J Exp Med*. 2011;223(3):223-226. doi:10.1620/tjem.223.223
4. Verma S, Gupta R, Kudesia M, Mathur A, Krishan G, Singh S. Coexisting iron deficiency anemia and beta thalassemia trait: effect of iron therapy on red cell parameters and hemoglobin subtypes. *ISRN Hematol*. 2014;2014:293216. doi:10.1155/2014/293216
5. Kravets I. Hyperthyroidism: diagnosis and treatment. *Am Fam Physician*. 2016;93(5):363-370.
6. Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. *Therap Adv Gastroenterol*. 2011;4(3):177-184. doi:10.1177/1756283X11398736
7. Ebert BL, Mak R, Pretz JL, et al. High throughput screen to identify small molecules that differentially regulate expression of the globin genes. *Blood*. 2005;106(11):3632. doi:10.1182/blood.V106.11.3632
8. Jaafer FH, Al-Tememi WF, Ali HH. The influence of thyroid status on hemoglobin A₂, F expression. *New Iraqi J Med*. 2009;5(3):78-81. Accessed March 27, 2022. https://applications.emro.who.int/imemrf/New_Iraqi_J_Med/New_Iraqi_J_Med_2009_5_3_78_81.pdf
9. Akasheh MS. Graves' disease mimicking beta-thalassemia trait. *Postgrad Med J*. 1994;70(822):300-301. doi:10.1136/pgmj.70.822.300
10. Al-Amadi AM, Ghanem NZ, Aldakeel SA, et al. Hemoglobin A₂ (HbA₂) has a measure of unreliability in diagnosing β -thalassemia trait (β -TT). *Curr Med Res Opin*. 2018;34(5):945-951. doi:10.1080/03007995.2018.1435520
11. Ahmed SS, Mohammed AA. Effects of thyroid dysfunction on hematological parameters: case controlled study. *Ann Med Surg (Lond)*. 2020;57:52-55. doi:10.1016/j.amsu.2020.07.008
12. Sharma P, Das R, Trehan A, et al. Impact of iron deficiency on hemoglobin A2% in obligate β -thalassemia heterozygotes. *Int J Lab Hematol*. 2015;37(1):105-111. doi:10.1111/ijlh.12246
13. Maheshwari KU, Rajagopalan B, Samuel TR. Variations in hematological indices in patients with thyroid dysfunction. *Int J Contemp Med Res*. 2020;7(1):A5-A7. doi:10.21276/ijcmr.2020.7.1.9
14. Dorgalaleh A, Mahmoodi M, Varmaghani B, et al. Effect of thyroid dysfunctions on blood cell count and red blood cell indice. *Iran J Ped Hematol Oncol*. 2013;3(2):73-77.
15. Hegazi MO, Ahmed S. Atypical clinical manifestations of graves' disease: an analysis in depth. *J Thyroid Res*. 2012;2012:768019. doi:10.1155/2012/768019
16. Gianoukakis AG, Gupta S, Tran TN, Richards P, Yehuda M, Tomassetti SE. Graves' disease



patients with iron deficiency anemia: serologic evidence of co-existent autoimmune gastritis. *Am J Blood Res.* 2021;11(3): 238-247.

17. Zhang Y, Xue Y, Cao C, et al. Thyroid hormone regulates hematopoiesis via the TR-KLF9 axis. *Blood.* 2017;130(20): 2161-2170. doi:10.1182/blood-2017-05-783043

18. Ma Y, Freitag P, Zhou J, Brüne B, Frede S, Fandrey J. Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. *Am J Physiol Regul Integr Comp Physiol.* 2004;287(3):R600-R607. doi:10.1152/ajpregu.00115.2004

19. Valencia ME, Kyaw Y, Chinnasamy E. Hyperthyroidism as an under-recognized reversible cause of microcytosis. *Endocrine Abstracts.* 2021;74:NCC17. doi:10.10.1530/endoabs.74. NCC17

20. Brining L, Cadre RR. Graves' disease with leukopenia and microcytosis. In: *Proceedings of UCLA Healthcare Volume 19.* Department of Medicine - UCLA; 2015. Accessed March 27, 2022. <https://proceedings.med.ucla.edu/wp-content/uploads/2016/11/Graves%2080%99-Disease-with-Leukopenia-and-Microcytosis.pdf>

21. Blanc L, Papoin J, Vidal M, et al. Ineffective erythropoiesis is the major cause of microcytic anemia in the TSAP6/Steap3 null mouse model. *Blood.* 2014;124(21):1332. doi:10.1182/blood.V124.21.1332. 1332

22. Gil-Morales C, Costa M, Tenant K, Hibbert A. Incidence of microcytosis in hyperthyroid cats referred for radioiodine treatment. *J Feline Med Surg.* 2021;23(10):928-935. doi:10.1177/1098612X20983973

ภาวะไตรอยด์เกิน ลงไปสูงการวินิจฉัยแบบต้าชาลัสซีเมียແงเทียม

ลิขสิทธิ์ แสงสุทอง¹, สมชาย อินทรศิริพงษ์², วัฒน์ อินทรศิริพงษ์³

¹ กลุ่มงานอายุรกรรม โรงพยาบาลกรุงเทพเมืองราช ราชบุรี ประเทศไทย

² กลุ่มงานอายุรกรรม โรงพยาบาลเซนต์แมรี่ นครราชสีมา ประเทศไทย

³ กลุ่มงานเวชปฏิบัติทั่วไป โรงพยาบาลพรัตนราชธานี กรุงเทพฯ ประเทศไทย

ผู้ป่วยที่โลหิตจางเล็กน้อย มีขบวนเม็ดเลือดแดงเล็ก ติดสีจาง และมีสัดส่วนฮีโมโกลบินเอ 2 (Hemoglobin [Hb] A₂) เพิ่มขึ้นเล็กน้อย การวินิจฉัยที่เป็นไปได้มากที่สุดคือ ภาวะเบต้าชาลัสซีเมียແง ในรายงานนี้ แม้ผู้ป่วยจะตรวจพบสิ่งเหล่านี้ทั้งหมด แต่ไม่มีภาวะเบต้าชาลัสซีเมียແง ผู้ป่วยเป็นชายไทยอายุ 14 ปี nanoprecipitate ด้วยการอ่อนเพลียและชี้ร้อน เป็นเวลา 2 สัปดาห์ ตรวจร่างกายพบต่อมไตรอยด์โตเล็กน้อย ชีพจร 100 ครั้งต่อนาที ผลตรวจเลือดพบ Hb 120 g/L, mean corpuscular volume (MCV) 72.1 fL, mean corpuscular hemoglobin (MCH) 23.3 pg/cell, free triiodothyronine (FT₃) > 20 pg/mL, free thyroxine (FT₄) > 5.0 ng/dL, thyrotropin < 2.5 mIU/L, serum ferritin 51.3 µg/L, Hb A₂ 3.8% นอกเหนือจากภาวะชอร์โมนไตรอยด์สูงปัจจุบันแล้ว การวินิจฉัยอีกอย่างคือ ภาวะเบต้าชาลัสซีเมียແง แพทย์ให้การรักษาด้วยยาต้านไตรอยด์จนครบ 6 เดือน ตรวจเลือดซ้ำพบว่า ชอร์โมนไตรอยด์เก็บปกติ Hb 146 g/L, MCV 83.3 fL, MCH 26.3 pg/cell, Hb A₂ 3.0% ซึ่งไม่เพียงระดับชอร์โมนไตรอยด์เท่านั้นที่ปกติ แต่ความเข้มข้นฮีโมโกลบินขนาดเม็ดเลือดแดง และสัดส่วนของฮีโมโกลบินเอ 2 ก็ปกติด้วย ผลการตรวจวิเคราะห์ยืนยันพบว่า ไม่พบยืนยันเบต้าชาลัสซีเมีย และคำดับยืนยันของสายเบต้าโกลบินก็พบว่าปกติ จึงอาจสรุปว่าภาวะชอร์โมนไตรอยด์ที่สูงเหล่านี้ยานำให้กับปกติมีสัดส่วนของฮีโมโกลบินเอ 2 เพิ่มขึ้นเล็กน้อย มีโลหิตจางเล็กน้อยแบบเม็ดเลือดแดงมีขนาดเล็กและติดสีจาง นำไปสู่การวินิจฉัยภาวะเบต้าชาลัสซีเมียແงเทียม อาจกล่าวได้อีกนัยหนึ่งว่า การตรวจวิเคราะห์ชนิดของชอร์โมนโกลบินในผู้ป่วยที่มีภาวะชอร์โมนไตรอยด์สูง ควรร่องกว่าเข้าสู่ภาวะไตรอยด์ปกติ

คำสำคัญ: ภาวะชอร์โมนไตรอยด์สูง ภาวะเบต้า ชาลัสซีเมีย ແงเทียม

Rama Med J: doi:10.33165/rmj.2022.45.3.256975

Received: March 27, 2022 Revised: September 1, 2022 Accepted: September 16, 2022

Corresponding Author:

ลิขสิทธิ์ แสงสุทอง
กลุ่มงานอายุรกรรม
โรงพยาบาลกรุงเทพเมืองราช
59/3 ถนนเพชรเกษม
ตำบลหนองเมือง อำเภอเมือง
ราชบุรี 70000 ประเทศไทย
โทรศัพท์ +668 4911 5775
อีเมล lickhasit1986@gmail.com

